

Bridging Supply Chain Gaps in Clinical Trial Logistics for mRNA Vaccines
Article Summary:
The rapid spread of the original virus strain and its subsequent variants across the globe highlighted the importance of vaccine technologies which were capable of swift deployment for human trials with efficacy and safety remaining top priorities.
Challenges in the mRNA vaccine supply chain
As mRNA vaccines take centre stage, the challenges surrounding their formulation and stability are now readily apparent. One of the major challenges of mRNA vaccine technology is its dependency on cold chain shipping and storage. Vaccines need to be shipped and stored at very low temperatures. This requires freezers capable of handling temperatures of −80°C which are not readily available at every clinical trial site. As vaccines are subject to strict regulatory controls to ensure their safety and efficacy the cold chain shipping infrastructure needs to be in place if mRNA vaccines are to realize their full potential.
Logistics providers connect the dots with hi-tech future-focused solutions
Logistics companies are playing an important role in building reliability in healthcare supply chains using end-to-end solutions for storage and transportation at specific temperatures from the point of manufacture to the healthcare facilities where they will be used. As a trusted partner in clinical trial and healthcare logistics, FedEx is well-positioned to handle mRNA vaccine shipments around the world. So far it has supported shipments of COVID-19 vaccines to more than 60 countries and territories around the world since 2020.